



P R Raghavan

Nanorx INC, USA

Metadichol®: A novel vitamin D receptor inverse/protean agonist and a vitamin D substitute

Metadichol (US patent 8,722,093 and 9043,383) is a nanoemulsion of long-chain alcohols found in many foods that are present in foods such as rice, sugar cane, wheat, peanuts. Metadichol acts as inverse/Protean agonist on Nuclear Vitamin D receptors (VDR) (US patent 9,006,292) that are present in cells throughout the body to stimulate the immune system. Metadichol® is first of a class of novel nano-emulsion molecules which are a safe and effective inhibitors of various biomarkers that affect many human diseases especially in the area of endocrine disorders. Here, in addition to acting on VDR, it shows cross reactivity against other nuclear receptors and how this leads to mitigation of infections including gene expression analysis and human

clinical case studies will be presented. Because it consists of natural components of conventional foods and has no known adverse side effects. Metadichol has the potential to serve as a novel, vitamin D substitute for the widespread deficiency that exists worldwide and overcome many chronic diseases.

Speaker Biography

P R Raghavan is the CEO of Nanorx Inc. He has a PhD in Organic Chemistry from Oregon State University (1979) and an MS in Chemistry (1972) from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and international patents and another 15 pending patent applications.

e: raghavan@nanorxinc.com

 Notes: